Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Exelixis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Exelixis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Exelixis Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Exelixis Enters into Agreement with Roche 11
Exelixis Enters into Agreement with Bristol-Myers Squibb 12
Exelixis Enters Into Distribution Agreement With Swedish Orphan Biovitrum For Cometriq 13
Exelixis Amends Distribution Agreement with Swedish Orphan Biovitrum for Cometriq 15
Licensing Agreements 17
Exelixis Enters into Licensing Agreement with Invenra 17
Exelixis Enters into Licensing Agreement with Stemsynergy Therapeutics 18
Takeda Pharma Enters into Licensing Agreement with Exelixis 19
Ipsen Amends Licensing Agreement with Exelixis 20
Equity Offering 22
Exelixis Raises USD155 Million in Public Offering of Shares 22
Exelixis Completes Public Offering Of Shares For US$80 Million 23
Exelixis Completes Public Offering Of Common Stock For US$147 Million 24
Exelixis Completes Public Offering Of Common Stock For US$69 Million 25
Debt Offering 27
Exelixis Completes Public Offering Of Senior Convertible Notes Due 2019 For US$288 Million 27
Exelixis Inc – Key Competitors 29
Exelixis Inc – Key Employees 30
Exelixis Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Aug 01, 2018: Exelixis announces second quarter 2018 financial results and provides corporate update 32
May 02, 2018: Exelixis Reports First Quarter 2018 Financial Results 35
Feb 26, 2018: Exelixis Reports Fourth Quarter and Full Year 2017 Financial Results 38
Nov 01, 2017: Exelixis Announces Third Quarter 2017 Financial Results and Provides Corporate Update 41
Aug 02, 2017: Exelixis Announces Second Quarter 2017 Financial Results and Provides Corporate Update 44
May 01, 2017: Exelixis Announces First Quarter 2017 Financial Results and Provides Corporate Update 47
Feb 27, 2017: Exelixis Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 50
Corporate Communications 54
Apr 09, 2018: Exelixis Elects Dr. Maria Freire to Its Board of Directors 54
Legal and Regulatory 55
Jan 09, 2017: Genentech withdraws counterclaim against Exelixis 55
Product News 56
10/16/2017: Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell Carcinoma 56
04/19/2018: Drug Combination Targeting Heat Shock Protein 90 and BRAF is Safe and Effective in Advanced Melanoma Patients 58
Product Approvals 59
Sep 08, 2017: Ipsen receives validation from European Medicines Agency for the application of a new indication for Cabometyx (cabozantinib) for first-line treatment of advanced renal cell carcinoma in adults 59
Aug 16, 2017: Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX for the Treatment of Previously Untreated Advanced Kidney Cancer 61
Jul 10, 2017: Kidney Cancer UK delighted NICE recommends cabozantinib on NHS for kidney cancer patients 63
Jul 10, 2017: Life-extending tablet for advanced kidney cancer, Cabometyx (cabozantinib), approved by NICE for routine access by English and Welsh patients 64
Jun 12, 2017: Scotland first in UK to make Cabometyx (cabozantinib) routinely available for individuals living with advanced kidney cancer 65
Mar 06, 2017: Exelixis’ Cabozantinib Granted Orphan Drug Designation for the Treatment of Hepatocellular Carcinoma 66
Clinical Trials 67
Nov 21, 2017: Exelixis Announces Phase 3 CELESTIAL Trial Results of Cabozantinib in Previously Treated Advanced Hepatocellular Carcinoma to be Presented at 2018 Gastrointestinal Cancers Symposium 67
Oct 16, 2017: Exelixis’ Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma 68
Oct 16, 2017: Ipsen announces that phase 3 CELESTIAL trial of cabozantinib meets primary endpoint of overall survival in patients with advanced hepatocellular carcinoma 70
Sep 09, 2017: Exelixis and Ipsen Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017 71
Sep 06, 2017: Exelixis to Co-Host Investor/Media Briefing to Discuss Data Presented at the ESMO 2017 Congress 73
Sep 04, 2017: Ipsen To Present 7 Abstracts on Cabometyx at European Society of Medical Oncology congress 74
Aug 01, 2017: Exelixis to Feature Presentations on Cabozantinib at ESMO 2017 Congress 76
Jun 19, 2017: Ipsen and its Partner Exelixis Announce Independent Radiology Committee Review Confirms Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma 79
Jun 12, 2017: Exelixis Announces Initiation of Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors 80
Jun 01, 2017: Ipsen To Present New Data of Cabometyx at ASCO 81
Feb 17, 2017: Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Metastatic Urothelial Carcinoma and Other Genitourinary Tumors 83
Other Significant Developments 85
Sep 07, 2017: Exelixis Debuts New Mission-Driven Corporate Branding That Supports Upcoming Milestones and Growth Strategy 85
Appendix 86
Methodology 86
About GlobalData 86
Contact Us 86
Disclaimer 86
Exelixis Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Exelixis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Exelixis Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Exelixis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Exelixis Enters into Agreement with Roche 11
Exelixis Enters into Agreement with Bristol-Myers Squibb 12
Exelixis Enters Into Distribution Agreement With Swedish Orphan Biovitrum For Cometriq 13
Exelixis Amends Distribution Agreement with Swedish Orphan Biovitrum for Cometriq 15
Exelixis Enters into Licensing Agreement with Invenra 17
Exelixis Enters into Licensing Agreement with Stemsynergy Therapeutics 18
Takeda Pharma Enters into Licensing Agreement with Exelixis 19
Ipsen Amends Licensing Agreement with Exelixis 20
Exelixis Raises USD155 Million in Public Offering of Shares 22
Exelixis Completes Public Offering Of Shares For US$80 Million 23
Exelixis Completes Public Offering Of Common Stock For US$147 Million 24
Exelixis Completes Public Offering Of Common Stock For US$69 Million 25
Exelixis Completes Public Offering Of Senior Convertible Notes Due 2019 For US$288 Million 27
Exelixis Inc, Key Competitors 29
Exelixis Inc, Key Employees 30
Exelixis Inc, Subsidiaries 31
List of Figures
Exelixis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Exelixis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9